- Home
- » Tags
- » Clofarabine
Top View
- FDA Listing of Established Pharmacologic Class Text Phrases January 2021
- Ara-C) in Relapsed and Refractory Acute Leukemias
- The Structural Basis for Cancer Drug Interactions with the Catalytic and Allosteric Sites of SAMHD1
- A Multicenter Trial of Myeloablative Clofarabine and Busulfan
- 2012 NIOSH List of Antineoplastic and Other Hazardous Drugs
- Instructional Template for Therapeutic Protocol
- Appendix B - Product Name Sorted by Applicant
- Novel Therapies for Children with Acute Myeloid Leukaemia
- Maintenance Therapy with Alternating Azacitidine and Lenalidomide in Elderly fit Patients with Poor Prognosis Acute Myeloid Leukemia: a Phase II Multicentre FILO Trial
- 2019 Table of Drugs
- Clofarabine in Clinical Haematology
- How to Order Chemotherapy at Shands at the University of Florida - Inpatient
- Clofarabine Salvage Therapy in Refractory Multifocal Histiocytic
- The Combination of Clofarabine, Etoposide, and Cyclophosphamide
- Emetogenic Potential of Antineoplastic Agents
- “What's New” Medical Pharmaceutical Policy Updates March
- Protocol Template
- NCCN Guidelines for Acute Myeloid Leukemia from the 1.2014 Version Include
- Extravasation
- The Use of Low-Dose Protracted Oral Clofarabine in a Patient with Myelodysplastic Syndrome After Failing 5-Azacitidine
- State and Specialty Pharmacy Drug Reimbursement Rates
- Evoltra, INN-Clofarabine
- Protocol CLO222: a Phase II, Open-Label Study of Clofarabine in Pediatric Patients with Refractory Or Relapsed Acute Myelogenous Leukemia
- Clofarabine Increases the Eradication of Minimal Residual Disease Of
- Guidelines for the Diagnosis and Treatment of Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia Nordic MDS Group
- Leukemia ~ Study #1
- Clinical Update
- The Addition of Arsenic Trioxide to Low-Dose Ara-C in Older Patients with AML Does Not Improve Outcome
- A Phase IB Study
- Cardio-Oncology: Why Cancer Needs a Heart Doctor
- Phase I Trial of Bortezomib and Clofarabine in Refractory MDS, Lymphomas, Or Solid Tumors
- Severe Toxicity of Clofarabine Combined to Cyclophosphamide and Etoposide in Two Children with Relapsed Acute Lymphoblastic Leukaemia (ALL)
- Skin Toxicity Associated with Clofarabine and Cytarabine for the Rt Eatment of Acute Leukemia Bingnan Zhang Yale School of Medicine, [email protected]
- Clofarabine/Busulfan-Based Reduced Intensity Conditioning Regimens
- Clofarabinecytarabinever1
- AML 17 Protocol Version
- Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients
- Therapeutic Drug Monitoring of Busulfan in Patients Undergoing Hematopoietic Cell Transplantation: a Pilot Single-Center Study in Taiwan
- Phase II Trial of Clofarabine with Topotecan, Vinorelbine, and Thiotepa in Pediatric Patients with Relapsed Or Refractory Acute Leukemia
- Acute Leukaemias and Myeloid Neoplasms Part 2: Acute Myeloid Leukaemia
- Acute Lymphoblastic Leukaemia September 2018
- A Phase I/II Study of Clofarabine in Combination with Cytarabine and Liposomal Daunorubicin in Children with Relapsed/Refractory Pediatric AML
- Clofarabine Combined with Etoposide and Cyclophosphamide For
- NHS England Evidence Review: Clofarabine As a Treatment For
- Chemotherapy Diluent-Rate Guide
- The Antimetabolites
- Clofarabine, Cyclophosphamide and Etoposide As Single-Course Re-Induction Therapy for Children with Refractory/Multiple Relapsed Acute Lymphoblastic Leukaemia
- Aminolevulinic Acid)- Updated Policy
- Do Not Tube List
- CLOLAR (Clofarabine) Must Be Administered Under the Supervision of a Physician Qualified in the Use of Antineoplastic Agents
- Thiotepa-Clofarabine-Busulfan with Allogeneic Stem Cell Transplant for High Risk Malignancies
- Novel Approaches for Therapy of Resistant Acute Lymphoblastic Leukemia
- Synergistic Anticancer Activity of Resveratrol in Combination with Docetaxel in Prostate Carcinoma Cells
- The Developing Role of Clofarabine in Acute Leukemias
- Approach to AML Treatment. Survey Results
- Hazardous Drug List
- Clofarabine for Acute Myeloid Leukaemia in Older Adults for Whom Anthracycline- Containing Combination Chemotherapy Is Inappropriate – First Line
- Emergent Radiotherapy for Leukemia-Induced Cranial Neuropathies Refractory to Intrathecal Therapy
- CLOLAR® Generic Name: Clofarabine Formulation: 1Mg/Ml Solution F
- The Use of Low-Dose Protracted Oral Clofarabine in a Patient with Myelodysplastic Syndrome After Failing 5-Azacitidine